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Abstract: 
The left ventricular ejection fraction (LVEF) test rate is increasingly used as a quality of care indicator for pa-
tients with heart failure. Our study produced benchmark LVEF test rates in a Medicare fee-for-service 
population for consideration by a clinical panel assembled by the Health Care Financing Administration. Our 
sample consisted of 46,583 beneficiaries admitted to the hospital for heart failure and with a complete set of 
Medicare fee-for- service bills dated 1996 or 1997. The national 2-year LVEF test rate was 79% for Medicare 
fee-for-service beneficiaries hospitalized for heart failure. Except for 1 state, the test rate ranged from 61% to 
89% across states. Our analysis demonstrates the feasibility of using billing data to compute LVEF test rates. 
Using a 2-year time window and measuring tests performed in outpatient as well as inpatient settings, we find a 
higher LVEF test rate than has been reported by most previous studies. 
Key words: Heart failure, Left ventricular ejection fraction, Medicare + Choice, Medicare fee-for-service, 
Quality of care. 
 
Article: 
According to the American Heart Association, approximately 3 million Americans are currently diagnosed with 
heart failure. Among these patients, more than 80% are over the age of 65, and most are Medicare enrollees (1). 
Heart failure is the leading cause of hospital admission among Medicare beneficiaries, with approximately 
700,000 hospitalizations each year. In the past decade, explicit criteria to evaluate the quality of care for patients 
with heart failure have been developed. The Agency for Health Care Policy and Research released a clinical 
practice guideline for heart failure in 1994 based on a comprehensive review of the scientific literature (2). The 
guideline stated that the heart failure category (systolic vs diastolic) should be defined and angiotensin-
converting enzyme inhibitors should be prescribed for patients with systolic dysfunction, unless specific 
contraindications are present. 
 
An increasing number of studies have used or recommended the left ventricular ejection fraction (LVEF) test 
rate as a quality of care indicator for patients with heart failure (3-8). The guideline issued by the American 
Society of Health-System Pharmacists in 1997 states that "Measurement of left-ventricular performance is a 
critical step in the evaluation and management of almost all patients with suspected or clinically evident heart 
failure" (9). The Health Care Financing Administration (HCFA) is using the LVEF test rate as one measure of 
quality of care of Medicare beneficiaries with heart failure, based on recommendations of the American College 
of Cardiology, American Heart Association, and Agency for Health Care Policy and Research (10). Recently, 
HCFA established a policy of extra payments to Medicare managed care organizations that demonstrate that 
they have exceeded threshold levels for LVEF test rates and angiotensin- converting enzyme inhibitor 
prescription rates among their enrollees hospitalized for heart failure (11). 
 
Through an extensive literature search, we identified 6 studies that reported LVEF test rates (4-8, 10). Four of 
the 6 studies' subjects were Medicare fee-for- service beneficiaries. One study (5) targeted Medicare 
beneficiaries, but it is unclear whether it included only fee-for-service patients, only managed care patients, or 
both. Another study (7) did not specifically target Medicare beneficiaries. Three of the 6 studies (4-6) were 
conducted in single states, 2 studies (7, 8) were conducted in multiple states, and 1 study (10) was based on 
national sample data and reported estimates for all states. Two studies (5, 8) randomly selected participant 
hospitals; 3 other studies (4, 6, 7) selected participating hospitals on a volunteer basis. The number of patients 
with heart failure included in the studies ranged from 522 (7) to 17,764 (10). The 6 studies reported LVEF test 
rates for hospitalized patients with heart failure ranging from 53% to 83%. 
 
We conducted an analysis using administrative billing data of LVEF test rates for Medicare fee-for-service 
enrollees hospitalized for heart failure. The purpose of our study was to produce benchmark LVEF test rates in 
a Medicare fee-for-service population for consideration by a clinical panel assembled by HCFA (12). The 
clinical panel suggested threshold rates for LVEF testing and angiotensin-converting enzyme inhibitor pre-
scription that Medicare managed care organizations must meet or exceed to receive extra payment for high- 
quality care of patients with heart failure. Our study represents an advance over previous studies in 3 key 
respects. First, we measured LVEF tests over a 2-year period, whereas all previous studies measured LVEF 
tests during single inpatient episodes only. Second, we included LVEF tests in outpatient settings in measuring 
test rates. Third, we employed a nationally representative random sample of Medicare beneficiaries that is much 
larger and therefore more statistically accurate than any previous study sample. 
 
METHODS 
Sample Selection 
To investigate national patterns of LVEF testing for patients with heart failure, we used a 5% random sample of 
Medicare beneficiaries for 1996 and 1997. We identified patients with at least 1 principal discharge diagnosis of 
heart failure in 1996 or 1997, defined by International Classification of Disease, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, or 428.x. A total of 
56,150 patients with heart failure were identified. This sample was restricted to Medicare enrollees expected to 
have a complete set of fee- for-service bills describing their medical treatment in 1996 and 1997. The following 
were excluded: 1505 beneficiaries because they were not enrolled in both Medicare Part A and Part B for all 
months of 1996 and 1997 or until their death; 1483 beneficiaries who were hospice residents in either 1996 or 
1997; 4012 beneficiaries who were capitated managed care enrollees in either 1996 or 1997; 31 beneficiaries 
who were non-US residents at some time in 1996 or 1997; and 358 beneficiaries who had employment-based 
primary insurance in either 1996 or 1997. Also excluded were 2178 beneficiaries who were Medicare eligible 
because of end-stage renal disease in either 1996 or 1997. Sensitivity analysis was conducted by including and 
excluding beneficiaries first becoming eligible for Medicare after January 1, 1996, and beneficiaries who died 
before December 31, 1997. LVEF test rates were insensitive to including or excluding new Medicare enrollees 
and/or decedents. Our final analysis sample included new enrollees and decedents and consisted of 46,583 
beneficiaries admitted to the hospital for heart failure in 1996 or 1997 with a complete set of Medicare fee- for-
service bills. 
 
Identifying LVEF Tests 
A list of Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes indicating an LVEF test 
was provided to us by HCFA. We cross-walked these codes, using commercially available software, to ICD9-
CM procedure codes. ICD-9-CM procedure codes are used for hospital inpatient procedure coding, whereas 
CPT-4 codes are used in billing for physician services in either the inpatient or outpatient settings. Hospital 
outpatient departments predominantly use CPT-4 codes but may use ICD-9-CM codes. A beneficiary was 
considered to have had an LVEF test if 1 or more of these codes was present on an administrative claim 
submitted to HCFA for payment dated 1996 or 1997. Physician bills are expected to be sensitive and specific 
indicators of the performance of an LVEF test in any setting because physicians must submit a bill to be paid, 
and submitting a bill for an unperformed test constitutes fraud. Hospital bills, on the other hand, underidentify 
LVEF tests because reporting LVEF tests does not affect payment (which is based on Diagnosis Related Group 
assignment). 
 
We measured LVEF tests during the same 2-year period, 1996-1997, from which our sample of patients with 
heart failure was drawn. We did not use a beneficiary-specific 2-year window around an index admission, but 
rather the fixed 2-year period 1996-1997. This approach was used to be consistent with HCFA's payment policy 
for identifying LVEF tests, which al- 
 
 
 
lows tests to be documented for a period of years rather than only during a single hospitalization or for a ben-
eficiary-specific time window. 
 
Eighteen CPT-4 codes were used to identify LVEF tests. A complete list of these procedure codes and their 
frequencies in our data is available in our report to HCFA (12). By far the largest number of beneficiaries with 
LVEF tests (34,895) were identified by the CPT-4 procedure code 93307 ("Echo, transthoracic, real-time with 
image documentation [2D] with or without M-mode recording; complete"). The 18 CPT-4 codes cross-walked 
to only 4 ICD-9-CM procedure codes: Among the 4 matched ICD-9-CM codes, codes 88.72, "diagnostic 
ultrasound of heart," and 88.53, "angiocardiography of left heart structures," identified the largest numbers of 
beneficiaries with LVEF tests, 6509 and 6156, respectively. 
 
RESULTS 
LVEF Test Rates by Type of Bill, Procedure Code, and Place of Service 
LVEF test rates by type of bill (physician, hospital outpatient, or hospital inpatient) and procedure code (CPT-4 
or ICD-9-CM) among our sample of 46,583 beneficiaries hospitalized for heart failure are shown in Table 1. 
The values shown are 2-year rates of at least 1 LVEF test in 1996 or 1997 for beneficiaries hospitalized for 
heart failure at least once during those 2 years. Among these patients, 36,717 patients had documentation of an 
LVEF test, which was indicated by either CPT-4 or ICD-9-CM procedure codes; 9866 patients had no 
documentation of an LVEF test during the 2-year period. The LVEF test rate for the national sample was 79%. 
 
The test rate calculated from physician bills alone was 78%. Physician bills may be from any place of service, 
inpatient or outpatient, and are coded with CPT- 4 procedure codes only. The physician bill rate was very close 
to the total rate calculated from both physician and hospital bills, only 1% lower. Since physician bills identify 
almost all LVEF tests, we used physician bills to measure the test rate by place of service, as shown in Table 2. 
Most patients with congestive heart failure received their LVEF tests in the inpatient setting-68% of such 
patients received a test in the inpatient setting over the 2-year period. Only 15% received a test in the hospital 
outpatient or emergency department setting, and only 17% received a test in all other settings. (The rates by 
setting are not mutually exclusive: 1 person may have had LVEF tests in more than 1 setting.) 
 
Returning to Table 1, according to the hospital outpatient department bills, 5459 patients had an LVEF test 
indicated by either CPT-4 or ICD-9-CM procedure codes. The documented test rate was 12%. This rate was 
comparable to, but slightly lower than, the outpatient and emergency department rate of 15% computed from 
physician bills alone (Table 2). Hospital outpatient bills document most, but not all, tests occurring in the 
outpatient department. 
 
The ICD-9-CM procedure codes are the sole source for indicating LVEF tests from hospital inpatient bills. A 
total of 10,914 patients had documentation of LVEF 
 
 
tests on inpatient bills, implying a test rate of 23% (Table 1). This percentage is much lower than the inpatient 
rate of 68% documented from physician bills (Table 2). Coding of LVEF tests in hospital bills is incomplete, 
presumably because not coding LVEF tests does not affect payment (which is based on Diagnosis Related 
Group assignment), so there is no financial incentive or necessity to code these tests. 
 
In summary, we found an overall 1996-1997 LVEF test rate of 79% for Medicare fee-for-service beneficiaries 
hospitalized for heart failure in 1996 or 1997. Almost all beneficiaries with LVEF tests can be identified using 
physician bills alone (test rate, 78%). Using hospital bills alone will grossly underestimate the rate of LVEF 
testing. 
 
LVEF Test Rates by State 
We calculated LVEF test rates by state to examine geographic variation in the rate. The state rates in Table 3 
were computed using the same methodology used for our "total" rates in Table 1, that is, using both CPT- 4 and 
ICD-9-CM procedure codes for all places of service. To determine whether differences in rates by state were 
meaningful, 95% confidence intervals around the mean were constructed. Rates for the 50 states plus the 
District of Columbia and Puerto Rico are listed in Table 3. Recall that our sample excluded Medicare 
beneficiaries enrolled in capitated managed care. Hence, states with a high Medicare managed care penetration 
(for example, California and Arizona) have fewer heart failure admissions in our sample relative to their total 
Medicare-eligible population. 
 
Except for Wyoming, which had a much lower rate than the rest of the states (47%, based on only 51 patients 
with heart failure), the test rate ranged from 61% to 89% across states. New Jersey and New Hampshire had the 
highest rates, 89% and 88%, respectively. The states with the highest test rates were primarily located in the 
eastern part of the country. New York State had the largest number of fee-for-service beneficiaries with heart 
failure (3101) and also a high LVEF rate of 84%. The lowest rates other than those for Wyoming were for 
North Dakota (61%) and Oregon (64%). Many of the states with lower test rates are 
 
 
more rural in character than average, potentially indicating lesser access to care or practice style differences in 
rural areas. 
 
COMMENT 
The existing literature on LVEF testing has focused on the inpatient setting (3-8, 10). These studies abstracted 
data from patients' medical records for a single index hospitalization used to identify the sample of patients with 
heart failure. In contrast, our study used both inpatient and outpatient billing data to identify the LVEF test rate. 
Our study was also unique in using a 2-year time window (1996-1997) for capturing LVEF tests in either the 
inpatient or outpatient setting. In addition, in contrast to previous studies, our study used a large nationally 
representative random sample to analyze LVEF test rates. 
 
Because of the identification of outpatient tests and the longer time window, it is not surprising that our national 
LVEF test rate (79%) is higher than that found by most previous studies (range, 53% to 83%) (48, 10). A good 
comparison is to the study of Jencks et al (10), which examined inpatient charts for a sample of 17,764 
Medicare fee-for-service heart failure admissions for the years 1998-1999 nationwide and found an LVEF test 
rate of 64%. Our data, therefore, indicate that the LVEF test rate is 15 percentage points higher when outpatient 
tests are included and a 2-year time period is used. 
 
A national test rate of 79% is still below an ideal standard of care. The HCFA Clinical Panel on Quality 
Indicator Thresholds for Congestive Heart Failure (12) suggested that in an ideal world, a 90% LVEF test rate 
would represent an achievable high-quality standard of care. Approximately 10% of patients with heart failure 
would not be referred for an LVEF test because of terminal illness, hospice residence, dementia, or other 
considerations. Some states approach the 90% target rate, whereas others are far below (Table 3). 
 
In the real world, especially in managed care plans, the measured LVEF test rate is not likely to achieve the 
ideal standard. Three factors will limit the rate suggested by the HCFA Clinical Panel (12). First, medical 
practice is not perfect—physicians will not always order an LVEF test when indicated. Second, physicians' 
documentation of LVEF tests is incomplete. Third, existing documentation may not be readily available to an 
insurer or managed care plan. Some tests may be done before a patient joins a plan, or a plan may subcapitate 
providers with no data-reporting requirements. Moreover, interpretation of vague doc umentation may be 
difficult, and a heart failure diagnosis may be mistakenly coded, in which case no LVEF test is indicated. 
 
Taking these real world considerations and other data into account, the HCFA Clinical Panel (12) suggested a 
threshold rate of 70-80% for documented LVEF testing for Medicare managed care organizations to qualify for 
extra payment for high-quality heart failure care. After the panel discussion, HCFA (13) established an LVEF 
testing threshold of 75% for extra payment. Managed care organizations would also have to document 
prescription of angiotensin-converting enzyme inhibitors to at least 80% of their patients with heart failure who 
have left ventricular systolic dysfunction (determined by an LVEF test) to qualify for extra payment under 
HCFA's policy. 
 
Our analysis demonstrates the feasibility of using billing data to compute LVEF test rates. Previous studies have 
relied on medical chart review (3-8, 10). Chart review is very costly compared with administrative data 
analysis. To the extent that insurers or managed care organizations have access to automated claims or 
encounter data systems, they may provide a more cost- effective means of documenting LVEF test rates than 
chart reviews. We have also documented, however, that the completeness with which LVEF tests are recorded 
in claims data is closely linked to the use of such data in payment. Encounter data in capitated managed care 
organizations, which has not been used for payment, may initially grossly underrecord test performance. But if 
financial incentives are tied to quality of care process indicators as measured on encounter data, the 
completeness of such data can be expected to improve over time. 
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